Detalhe da pesquisa
1.
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Future Oncol
; 15(30): 3427-3433, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31509028
2.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296952
3.
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Cancer Gene Ther
; 31(4): 517-526, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146006
4.
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Front Oncol
; 13: 1176448, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342189
5.
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).
Front Immunol
; 14: 1104753, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36960054
6.
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
Clin Colorectal Cancer
; 22(1): 92-99, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529613
7.
Data Management 101 for drug developers: A peek behind the curtain.
Clin Transl Sci
; 16(9): 1497-1509, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382299
8.
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy.
Int J Radiat Oncol Biol Phys
; 116(3): 551-559, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646388
9.
RRx-001 and the "Right stuff": Protection and treatment in outer space.
Life Sci Space Res (Amst)
; 35: 69-75, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36336372
10.
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.
Am J Cancer Res
; 12(4): 1912-1918, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35530283
11.
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).
J Cancer
; 13(9): 2945-2953, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35912017
12.
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials.
Am J Cancer Res
; 12(9): 4448-4457, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36225630
13.
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta.
Am J Cancer Res
; 11(10): 5184-5189, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34765319
14.
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
Expert Opin Investig Drugs
; 30(2): 177-183, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306414
15.
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
J Med Chem
; 64(11): 7261-7271, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043360
16.
RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice.
Front Pharmacol
; 12: 676396, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33967816
17.
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Transl Lung Cancer Res
; 10(1): 274-278, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33569311
18.
BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.
Int J Radiat Oncol Biol Phys
; 107(3): 478-486, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32169409
19.
A note on improved statistical approaches to account for pseudoprogression.
Cancer Chemother Pharmacol
; 81(3): 621-626, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29404682
20.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Expert Opin Investig Drugs
; 26(1): 109-119, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27935336